EP2820028A1 - A process for preparing pure citicoline (cdp-choline) - Google Patents

A process for preparing pure citicoline (cdp-choline)

Info

Publication number
EP2820028A1
EP2820028A1 EP13755755.9A EP13755755A EP2820028A1 EP 2820028 A1 EP2820028 A1 EP 2820028A1 EP 13755755 A EP13755755 A EP 13755755A EP 2820028 A1 EP2820028 A1 EP 2820028A1
Authority
EP
European Patent Office
Prior art keywords
citicoline
acid
choline
dicarboxylic acid
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13755755.9A
Other languages
German (de)
French (fr)
Other versions
EP2820028A4 (en
Inventor
Rajiv Kumar
Yogendra CHAUHAN
Vilas DHAKE
Vijay Tambe
Atul WAGH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Frichem Private Ltd
Original Assignee
Frichem Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frichem Private Ltd filed Critical Frichem Private Ltd
Publication of EP2820028A1 publication Critical patent/EP2820028A1/en
Publication of EP2820028A4 publication Critical patent/EP2820028A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives

Definitions

  • the present invention relates to industrially feasible and economical process for preparing highly pure Citicoline (CDP-Choline) or sodium salt of Citicoline with the aid of dicarboxylic acid or its salts.
  • CDP-Choline naturally occurring nucleotide, is a neuroprotective indicated for the treatment of ischemic stroke and head trauma in patients.
  • Cicoline (CDP-Choline) is represented by formula (I).
  • US patent no. 3,666,748 discloses a process for preparing Citicoline sodium by reaction of 4- morpholino-N,N'-dicyclohexylcarboxamidine chloride salt of choline phosphormorpholidate (I) with cytidine-5-monophosphate in free form or its salts with base in a solvent such as o- chlorophenol, m-cresol, acetonitrile, pyridine and the like.
  • the Citicoline thus obtained is purified through a column chromatograph packed with activated carbon followed by elution to get ammonium salt of citicoline, which is further converted to citicoline followed by citicoline sodium.
  • US patent no. 3,787,392 discloses a process for preparing Citicoline by adding the acidic calcium phosporyl choline chloride tetra hydrate to the solution of morpholidiate cytidine 5- monophosphate and DCC in methanol followed by isolation and purification by means of chromatography column containing anion exchanger (Dowex 1x2 type formate form; 50-100 mesh) which is further converted to its sodium salt by neutralizing with sodium hydroxide. Further, US patent no.
  • 3,803,125 discloses a process for preparing citicoline by reacting morpholidiate cytidine 5 '-monophosphate with calcium phosporyl choline chloride tetra hydrate in solvent system of an aliphatic alcohol or dialkyl ketone or dimethyl formamide at pH from 1 to 6.5.
  • the product thus obtained is further isolated; purified by means of chromatography column containing anion exchanger; concentrated; and neutralized with aqueous solution of sodium hydroxide to get citicoline sodium.
  • the present invention provides a process for preparation of Citicoline sodium, which does not suffer from the above-mentioned disadvantages and provides desired compound with high yield and quality, in a short period of time, without formation of substantial amounts of disconcerting by-products.
  • One more object of the invention is to provide industrially feasible process to attain highly pure sodium salt of Citicoline (CDP-Choline) with minimum impurities where the purity attained is > 99%, measured by HPLC.
  • the present invention provides a process of removing the soluble impurities by means of dicarboxylic acid or its salt, during the preparation of sodium salt of Citicoline (CDP-Choline).
  • the invention provides a process for preparing Citicoline (CDP-Choline), wherein the process comprises reacting a cytidine S'-monophospahte or its amide salts with calcium phosphoryl choline chloride tetra hydrate or its amide salts in presence of dicyclohexyl carbodiimide (DCC) and a solvent, wherein a dicarboxylic acid or its salt is employed in the process to obtain citicoline with a purity of more than 99% measured by HPLC.
  • DCC dicyclohexyl carbodiimide
  • the process of the present invention further provides a process for preparing highly pure sodium salt of citicoline by reacting the pure citicoline obtained by the process of this invention with aqueous solution of sodium hydroxide.
  • the dicarboxylic acid used in the present invention is either in the form of free acid or its base salts.
  • the dicarboxylic acid is selected from the group consisting of oxalic acid, malonic acid, succininc acid, glutaric acid.
  • the base of dicarboxylic acid is selected from the group consisting of organic bases such as amidates, amines or inorganic base such as alkali or alkaline earth metal.
  • the solvent for carrying out the process is selected from the group consisting of aliphatic alcohols from C1-4 atoms, ketones such as acetone, methyl isobutyl ketone and the like or mixture thereof.
  • the solvent employed in the process is methanol.
  • the dicarboxylic acid or its salts lessen the solubility of inorganic impurities such as calcium chloride, calcium hydroxide, unreacted choline phosphate, 5- CMP. This results in obtaining higly pure Citicoline or sodium salt of Citicoline without employing column chromatography.
  • a process that employs dicarboxylic acid or its salts for lessening soluble inorganic impurities like calcium chloride, calcium hydroxide as well as unreacted choline phosphate, 5-CMP etc., during the process for preparing Citicoline or sodium salt of Citicoline, having HPLC purity > 99%.
  • CDP-Choline a process for preparing Citicoline (CDP-Choline) where the process comprises condensing cytidine 5'- monophospahte or its amidate salts with calcium phosphoryl choline chloride tetra hydrate or its amidate salts in presence of dicyclohexyl carbodiimide (DCC).
  • DCC dicyclohexyl carbodiimide
  • the reaction of cytidine 5 '-monophospahte or its amidate salt with calcium phosphoryl choline chloride or its amidate salt is generally carried out in a solvent selected from the group consisting of but not limited to aliphatic alcohols from Ci_4-atoms; ketone such as acetone, methyl isobutyl ketone and the like or mixture thereof; preferably methanol.
  • the reaction temperature generally ranges from 60°C to the reflux of the solvent employed.
  • dicarboxyhc acid is exercised either in the form of free acid or its base salts, provided that dicarboxyhc acid or its salts are employed at different juncture during the Citicoline (CDP-Chloine) synthesis.
  • Dicarboxyhc acid may include oxalic acid, malonic acid, succinic acid, glutaric acid and the like.
  • the base used herein for preparing the dicarboxyhc acid salt is selected from the group consisting of but not limited to organic bases such as amidates, amines; or inorganic base such as alkali or alkaline earth metal.
  • Amidates used herein may be used as mono and dialkyl-substituted amidates, the alkyl radicals of Ci_ 4 atoms, such as dimethylamidate, mono and diethyl-amidate, mono and dipropyl amidate, isopropyl-amidates and butyl-amidates, as well as the mixed amidates.
  • the alkyl radicals which are joined together directly or via a heteroatom to form a ring, for example, the morpholidates, piperidates, cyclohexylimidates and anilidates may also be used.
  • Amines including triethylamine, diisopropyl amine, etc. may also be used herein.
  • dicarboxyhc acid or its base salt is dependent on the starting material taken for the Citicoline preparation.
  • Dicarboxyhc acid is used herein at the start of the reaction, when cytidine 5 '-monophospahte is reacted with phosphoryl choline chloride amidates.
  • dicarboxyhc acid or its base salt is exercised with calcium phosphoryl choline chloride first to get the phosphoryl chlorine chloride, which is then converted to its amidates salt by reacting it with amidanes.
  • dicarboxyhc acid or its amidates contribute an important role in preparation of highly pure Citicoline having purity > 99% without the use of column chromatography.
  • the dicarboxyhc acid or its salts employed in the process convert the soluble impurities, generated during the reaction, into insoluble impurities, and the desired product with diminished amounts of impurities remains soluble in the solvent of reaction. Thereby insoluble impurities can be removed by a simple method of filtration, instead of non- feasible, prolonged column chromatography.
  • the citicoline produced by the process of this invention is easily recovered by known methods.
  • the resulting reaction mixture is extracted with a solvent, and the solvent extract is distilled out to obtain crude citicoline.
  • the solution of citicoline in water is purified by means of charcoal treatment and then concentrated to dryness to recover the objective compound with the purity of > 99%.
  • citicoline is treated with sodium hydroxide to get citicoline sodium with purity of > 99% measured by HPLC.
  • the reaction mass was cooled and filtered to get crude Citicoline by adding IPA. Further, morpholidiate salt of oxalic acid (138.3 gm) was added to the solution of crude citicoline in methanol at 30-35°C followed by the addition of IPA to get the precipitated Citicoline, which is further treated with activated charcoal in water followed by filtration. To filtrate containing purified Citicoline, aqueous solution of sodium hydroxide was added at room temperature followed by addition of ethanol and the temperature of reaction mass was raised to 50-55°C. The precipitated product was filtered and dried where the purity of citicoline sodium is > 99% measured by HPLC. (265 gm).

Abstract

Disclosed herein is a process for preparing highly pure Citicoline (CDP-Choline) or sodium salt of Citicoline with the aid of dicarboxylic acid or its salts. The process of the present invention results in Citicoline with a purity of more than 99% measured by HPLC.

Description

A PROCESS FOR PREPARING PURE CITICOLINE (CDP-CHOLINE)
Field of the Invention
The present invention relates to industrially feasible and economical process for preparing highly pure Citicoline (CDP-Choline) or sodium salt of Citicoline with the aid of dicarboxylic acid or its salts.
Background of the Invention
Citicoline (CDP-Choline), naturally occurring nucleotide, is a neuroprotective indicated for the treatment of ischemic stroke and head trauma in patients. Citicoline (CDP-Choline) is represented by formula (I).
US patent no. 3,666,748 discloses a process for preparing Citicoline sodium by reaction of 4- morpholino-N,N'-dicyclohexylcarboxamidine chloride salt of choline phosphormorpholidate (I) with cytidine-5-monophosphate in free form or its salts with base in a solvent such as o- chlorophenol, m-cresol, acetonitrile, pyridine and the like. The Citicoline thus obtained is purified through a column chromatograph packed with activated carbon followed by elution to get ammonium salt of citicoline, which is further converted to citicoline followed by citicoline sodium.
US patent no. 3,787,392 discloses a process for preparing Citicoline by adding the acidic calcium phosporyl choline chloride tetra hydrate to the solution of morpholidiate cytidine 5- monophosphate and DCC in methanol followed by isolation and purification by means of chromatography column containing anion exchanger (Dowex 1x2 type formate form; 50-100 mesh) which is further converted to its sodium salt by neutralizing with sodium hydroxide. Further, US patent no. 3,803,125 discloses a process for preparing citicoline by reacting morpholidiate cytidine 5 '-monophosphate with calcium phosporyl choline chloride tetra hydrate in solvent system of an aliphatic alcohol or dialkyl ketone or dimethyl formamide at pH from 1 to 6.5. The product thus obtained is further isolated; purified by means of chromatography column containing anion exchanger; concentrated; and neutralized with aqueous solution of sodium hydroxide to get citicoline sodium.
All the above prior art processes have several disadvantages from industrial and economical point of view, in particular, these methods employ costly and hazardous solvents in higher volume during reaction as well as for isolation. Not only that, quantity and quality of the desired product is hampered due to various by-products engendered during these processes as these by-products are highly soluble along with the desired product. In addition, column chromatography is employed for removal of all these by-products, which is costly, prolonged and non-feasible process on large scale.
To address the above-mentioned problems, the present invention provides a process for preparation of Citicoline sodium, which does not suffer from the above-mentioned disadvantages and provides desired compound with high yield and quality, in a short period of time, without formation of substantial amounts of disconcerting by-products.
Summary of the Invention
It is an object of the present invention to provide an efficient, commercially viable and highly productive process for preparing sodium salt of Citicoline (CDP-Choline) and thereby isolation of the same without means of column chromatography.
One more object of the invention is to provide industrially feasible process to attain highly pure sodium salt of Citicoline (CDP-Choline) with minimum impurities where the purity attained is > 99%, measured by HPLC.
In another object, the present invention provides a process of removing the soluble impurities by means of dicarboxylic acid or its salt, during the preparation of sodium salt of Citicoline (CDP-Choline).
In one aspect, the invention provides a process for preparing Citicoline (CDP-Choline), wherein the process comprises reacting a cytidine S'-monophospahte or its amide salts with calcium phosphoryl choline chloride tetra hydrate or its amide salts in presence of dicyclohexyl carbodiimide (DCC) and a solvent, wherein a dicarboxylic acid or its salt is employed in the process to obtain citicoline with a purity of more than 99% measured by HPLC.
In another aspect, the process of the present invention, further provides a process for preparing highly pure sodium salt of citicoline by reacting the pure citicoline obtained by the process of this invention with aqueous solution of sodium hydroxide. The dicarboxylic acid used in the present invention is either in the form of free acid or its base salts. In one aspect, the dicarboxylic acid is selected from the group consisting of oxalic acid, malonic acid, succininc acid, glutaric acid. In another aspect, the base of dicarboxylic acid is selected from the group consisting of organic bases such as amidates, amines or inorganic base such as alkali or alkaline earth metal.
In another aspect of the present invention, the solvent for carrying out the process is selected from the group consisting of aliphatic alcohols from C1-4 atoms, ketones such as acetone, methyl isobutyl ketone and the like or mixture thereof. In a preferred aspect, the solvent employed in the process is methanol.
In the present invention, the dicarboxylic acid or its salts lessen the solubility of inorganic impurities such as calcium chloride, calcium hydroxide, unreacted choline phosphate, 5- CMP. This results in obtaining higly pure Citicoline or sodium salt of Citicoline without employing column chromatography.
The above and other objects of the present invention are attained according to following preferred embodiments of the present invention. However the scope of the invention is not restricted to the particular embodiments discussed herein after.
Detailed Description of the Invention
While the invention is susceptible to various modifications and alternative forms, specific embodiment thereof will be described in detail below. It should be understood, however that it is not intended to limit the invention to the particular forms disclosed, but on the contrary, the invention is to cover all modifications, equivalents, and alternative falling within the scope of the invention as defined by the appended claims.
In accordance to one embodiment of the present invention, there is provided a process for preparing Citicoline (CDP-Choline) or sodium salt of Citicoline having HPLC purity > 99%, without employing column chromatography.
In accordance to another embodiment of the present invention, there is provided a process that employs dicarboxylic acid or its salts for lessening soluble inorganic impurities like calcium chloride, calcium hydroxide as well as unreacted choline phosphate, 5-CMP etc., during the process for preparing Citicoline or sodium salt of Citicoline, having HPLC purity > 99%.
According to one of the embodiments of the present invention, there is provided a process for preparing Citicoline (CDP-Choline) where the process comprises condensing cytidine 5'- monophospahte or its amidate salts with calcium phosphoryl choline chloride tetra hydrate or its amidate salts in presence of dicyclohexyl carbodiimide (DCC).
The reaction of cytidine 5 '-monophospahte or its amidate salt with calcium phosphoryl choline chloride or its amidate salt is generally carried out in a solvent selected from the group consisting of but not limited to aliphatic alcohols from Ci_4-atoms; ketone such as acetone, methyl isobutyl ketone and the like or mixture thereof; preferably methanol. The reaction temperature generally ranges from 60°C to the reflux of the solvent employed.
According to the process of the present invention, dicarboxyhc acid is exercised either in the form of free acid or its base salts, provided that dicarboxyhc acid or its salts are employed at different juncture during the Citicoline (CDP-Chloine) synthesis. Dicarboxyhc acid may include oxalic acid, malonic acid, succinic acid, glutaric acid and the like. The base used herein for preparing the dicarboxyhc acid salt is selected from the group consisting of but not limited to organic bases such as amidates, amines; or inorganic base such as alkali or alkaline earth metal.
Amidates used herein may be used as mono and dialkyl-substituted amidates, the alkyl radicals of Ci_4 atoms, such as dimethylamidate, mono and diethyl-amidate, mono and dipropyl amidate, isopropyl-amidates and butyl-amidates, as well as the mixed amidates. Further the alkyl radicals, which are joined together directly or via a heteroatom to form a ring, for example, the morpholidates, piperidates, cyclohexylimidates and anilidates may also be used. Amines, including triethylamine, diisopropyl amine, etc. may also be used herein. The choice for the use of dicarboxyhc acid or its base salt is dependent on the starting material taken for the Citicoline preparation. Dicarboxyhc acid is used herein at the start of the reaction, when cytidine 5 '-monophospahte is reacted with phosphoryl choline chloride amidates. At this time dicarboxyhc acid or its base salt is exercised with calcium phosphoryl choline chloride first to get the phosphoryl chlorine chloride, which is then converted to its amidates salt by reacting it with amidanes.
Further, on the other hand when Cytidine 5 '-monophospahte amidates is condensed with phosphoryl choline chloride, dicarboxyhc acid or its base salt is exercised on completion of condensation reaction.
The employment of dicarboxyhc acid or its amidates contribute an important role in preparation of highly pure Citicoline having purity > 99% without the use of column chromatography. The dicarboxyhc acid or its salts employed in the process, convert the soluble impurities, generated during the reaction, into insoluble impurities, and the desired product with diminished amounts of impurities remains soluble in the solvent of reaction. Thereby insoluble impurities can be removed by a simple method of filtration, instead of non- feasible, prolonged column chromatography.
Thus, the citicoline produced by the process of this invention is easily recovered by known methods. For example, the resulting reaction mixture is extracted with a solvent, and the solvent extract is distilled out to obtain crude citicoline. Further, the solution of citicoline in water is purified by means of charcoal treatment and then concentrated to dryness to recover the objective compound with the purity of > 99%. Moreover, citicoline is treated with sodium hydroxide to get citicoline sodium with purity of > 99% measured by HPLC.
The following examples are illustrative of the instant invention. These examples are not intended to limit the scope of the invention as defined herein above.
Example 1
To a solution of calcium phosphoryl choline chloride tetra hydrate (50.0 gm) in water, a solution of oxalic acid in RO water (19.5 gm oxalic acid in 90 ml RO water) was added at 45- 50°C. The reaction mass was filtered and distilled out to get residue followed by addition of methanol. To the above solution, solution of morpholine and DCC in methanol was added. The temperature of the reaction was raised to 50-55°C and to this, solution of cytidine 5'- monophospahte in methanol (12.2 gm in 40 ml methanolic HCl and 20 ml methanol) was added and reaction was maintained. The pH 3.5 of reaction mixture was maintained by methanolic HCl. Reaction mass was cooled and IPA was added after completion of the reaction. The precipitated product, citicoline, was filtered and dried. The crude Citicoline (16.0 gm) was dissolved in water and treated with charcoal to get the purified Citicoline acid which on reaction with aqueous sodium hydroxide gave Citicoline Sodium with purity > 99%.
Example 2
To the solution of cytidine 5'-monophospahate (5'-CMP) (100 gm) in methanol (750 ml), solution of morpholine (75 gm) and DCC (100 gm) in methanol was added at room temperature. The temperature of the reaction was raised to 50-55°C for a time period of 3-7 hrs followed by cooling the reaction mass and filtered to get morpholidiate cytidine 5'- monophospahate in mother liquor. To this, solution of calcium phosphoryl choline chloride (200 gm) in methanol was added and the temperature of reaction mass was raised to 50-55°C and maintained at pH of 3.5 by methanolic HCl. The reaction mass was cooled and filtered to get crude Citicoline by adding IPA. Further, morpholidiate salt of oxalic acid (138.3 gm) was added to the solution of crude citicoline in methanol at 30-35°C followed by the addition of IPA to get the precipitated Citicoline, which is further treated with activated charcoal in water followed by filtration. To filtrate containing purified Citicoline, aqueous solution of sodium hydroxide was added at room temperature followed by addition of ethanol and the temperature of reaction mass was raised to 50-55°C. The precipitated product was filtered and dried where the purity of citicoline sodium is > 99% measured by HPLC. (265 gm).

Claims

We Claim:
1. A process for preparing pure Citicoline (CDP-Choline), the process comprising:
reacting a cytidine 5'-monophospahte or its amide salts with calcium phosphoryl choline chloride tetra hydrate or its amide salts in presence of dicyclohexyl carbodiimide (DCC) and a solvent,
wherein a dicarboxylic acid or its salt is employed in the process to obtain citicoline with a purity of more than 99% measured by HPLC.
2. The process as claimed in claim 1, further comprising preparing highly pure sodium salt of citicoline by reacting the pure citicoline with sodium hydroxide.
3. The process as claimed in claim 1, wherein the dicarboxylic acid is used either in the form of free acid or its base salts.
4. The process as claimed in any one of the preceding claims, wherein dicarboxylic acid is selected from the group consisting of oxalic acid, malonic acid, succininc acid and glutaric acid.
5. The process as claimed in any one of the preceding claims, wherein the base of dicarboxylic acid is selected from the group consisting of organic bases such as amidates, amines or inorganic base such as alkali or alkaline earth metal.
6. The process as claimed in claim 1, wherein the solvent is selected from the group consisting of aliphatic alcohols from C atoms, ketones such as acetone, methyl isobutyl ketone and the like or mixture thereof.
7. The process as claimed in claim 1, wherein the solvent is methanol.
8. The process as claimed in any of the preceding claims, wherein the dicarboxylic acid or its salts lessen the solubility of inorganic impurities such as calcium chloride, calcium hydroxide, unreacted choline phosphate, 5-CMP.
EP13755755.9A 2012-02-28 2013-02-28 A process for preparing pure citicoline (cdp-choline) Withdrawn EP2820028A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN540MU2012 2012-02-28
PCT/IB2013/051585 WO2013128393A1 (en) 2012-02-28 2013-02-28 A process for preparing pure citicoline (cdp-choline)

Publications (2)

Publication Number Publication Date
EP2820028A1 true EP2820028A1 (en) 2015-01-07
EP2820028A4 EP2820028A4 (en) 2015-08-26

Family

ID=49081721

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13755755.9A Withdrawn EP2820028A4 (en) 2012-02-28 2013-02-28 A process for preparing pure citicoline (cdp-choline)

Country Status (2)

Country Link
EP (1) EP2820028A4 (en)
WO (1) WO2013128393A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104031105B (en) * 2014-06-06 2015-07-15 回音必集团(江西)东亚制药有限公司 Method for preparing citicoline sodium
CN105732752A (en) * 2016-03-18 2016-07-06 新乡学院 Citicoline and synthetic method thereof
CN106146590A (en) * 2016-06-29 2016-11-23 陈建峰 A kind of preparation method of C14H25N4NaO11P2
CN110684066B (en) * 2019-05-22 2020-12-08 广东金城金素制药有限公司 Cytophosphocholine medicinal preparation and new application thereof in cerebral infarction acute-stage disturbance of consciousness
CN113563377A (en) * 2021-07-15 2021-10-29 浙江蓝波新材料科技有限公司 Novel phosphorylcholine synthesis process technical method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3666748A (en) * 1967-12-18 1972-05-30 Takeda Chemical Industries Ltd Method for production of cytidine (or deoxycytidine)-5{40 -diphosphate choline and intermediates therefor
DE2059429C2 (en) * 1970-12-02 1986-10-23 Boehringer Mannheim Gmbh, 6800 Mannheim Process for the preparation of nucleoside diphosphate esters
CN102010454B (en) * 2010-12-02 2012-03-07 胡建荣 Citicoline sodium compound and new method thereof

Also Published As

Publication number Publication date
EP2820028A4 (en) 2015-08-26
WO2013128393A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
EP2820028A1 (en) A process for preparing pure citicoline (cdp-choline)
CA2848631C (en) Rilpivirine hydrochloride
WO2013047738A1 (en) Method for producing glufosinate p free acid
KR20110108409A (en) Method for synthesis of (1s, 2r)-milnacipran
JP5518936B2 (en) Method for producing high purity monopentaerythritol
JP7373598B2 (en) Method for producing dinucleoside polyphosphate compounds
EP0430336B1 (en) Process for the preparation of 4-O-phosphates of dopamine and dopamine derivatives
US20170218006A1 (en) Synthesis of Phosphoramidates
EP3782992A1 (en) Novel process for the preparation of ranolazine
JP2004527577A (en) Synthesis of 4-phenylbutyric acid
RU2434869C2 (en) Method of producing abacavir
JP2019522003A (en) Improved manufacturing process for the preparation of sofosbuvir
JP5785622B2 (en) Novel method for producing a folic acid antagonist having a glutamic acid moiety in its structure
NO326203B1 (en) Process for Preparation of SN, N'-Bis [2-hydroxy-1- (hydroxymethyl) ethyl] - [5 - [(2-hydroxy-1-oxopropyl) amino] -2,4,6-triiodo-1, 3-benzenedicarboxamide
US8952148B2 (en) Process for the preparation of taurolidine and its intermediates thereof
CN109836424B (en) Method for preparing caffeine by methylation of environment-friendly theophylline sodium salt
JP6947354B2 (en) How to make linagliptin
JP2006516148A (en) Method for extracting 2-keto-L-gulonic acid (KGA) from a polar, preferably aqueous solvent
CN112694445A (en) Purification method of oxalaggrin sodium intermediate
EP0053584B1 (en) Raceme sulpiride resolution process
HUT56050A (en) Process for resolving 2-amino-4phenyl-butane
CN101100432B (en) Method for synthesizing benzyldimethyl[3-(myristamide)propyl]ammonium chloride
JP5334852B2 (en) Abacavir manufacturing method
JP4330097B2 (en) 2- (Hydroxycarbonyl) ethyl-3-amino-3- (hydroxycarbonyl) propylphosphinic acid and method for producing the same
KR20080097708A (en) Process for preparation of sarpogrelate hcl salt

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140822

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150728

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 1/00 20060101ALI20150722BHEP

Ipc: C07H 19/10 20060101AFI20150722BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160225